Dr Ing Hcf Stock Beta
| P911 Stock | 59.22 0.04 0.07% |
Dr Ing hcF fundamentals help investors to digest information that contributes to Dr Ing's financial success or failures. It also enables traders to predict the movement of P911 Stock. The fundamental analysis module provides a way to measure Dr Ing's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Ing stock.
P911 |
Dr Ing hcF Company Beta Analysis
Dr Ing's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Dr Ing hcF has a Beta of 0.0. This is 100.0% lower than that of the Consumer Cyclical sector and 100.0% lower than that of the Auto Manufacturers industry. The beta for all Germany stocks is 100.0% lower than that of the firm.
P911 Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Ing's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Ing could also be used in its relative valuation, which is a method of valuing Dr Ing by comparing valuation metrics of similar companies.Dr Ing is currently under evaluation in beta category among its peers.
P911 Fundamentals
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.20 % | |||
| Shares Owned By Insiders | 7.00 % | |||
| Shares Owned By Institutions | 13.64 % | |||
| Revenue | 36.76 B | |||
| Gross Profit | 8.99 B | |||
| EBITDA | 9.38 B | |||
| Book Value Per Share | 251.94 X | |||
| Number Of Employees | 36.52 K |
About Dr Ing Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Ing hcF's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Ing using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Ing hcF based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in P911 Stock
Dr Ing financial ratios help investors to determine whether P911 Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in P911 with respect to the benefits of owning Dr Ing security.